Piper Sandler Analysts Bullish on Allogene Therapeutics (ALLO) Ahead of Key ALPHA3 Data Readout

Allogene Therapeutics, Inc. (NASDAQ:ALLO) is one of the 10 most active penny stocks to buy.

Piper Sandler Analysts Bullish on Allogene Therapeutics (ALLO) Ahead of Key ALPHA3 Data Readout

On March 13, 2026, Biren Amin, an analyst at Piper Sandler, maintained an “Overweight” rating on Allogene Therapeutics, Inc. (NASDAQ:ALLO) and increased the price target of the stock from $7 to $8.

Amin noted increased anticipation surrounding the company’s upcoming clinical catalyst. The interim analysis of the Phase 2 ALPHA3 study, which is assessing cemacabtagene ansegedleucel (cema-cel) as a first-line consolidation therapy for large B-cell lymphoma, remains the primary focus of investors, according to Amin. The data, which is anticipated to be released in April 2026, will evaluate the clearance of minimal residual disease (MRD). Piper believes that the setup is auspicious for cema-cel to achieve a 25%–30% MRD clearance advantage over observation.

The positive news follows Allogene Therapeutics, Inc. (NASDAQ:ALLO)’s March 12, 2026, fourth-quarter and full-year 2025 update, which identified the ALPHA3 trial as a potential inflection point for its allogeneic CAR-T platform. The trial will recruit more than 60 locations worldwide and will evaluate whether early MRD-guided treatment can prevent lymphoma relapse.

Regarding the company’s financials, Allogene Therapeutics, Inc. (NASDAQ:ALLO) reported a Q4 2025 net loss of $38.81 million, or $0.17 per share, and completed the year with $258.30 million in cash, extending its runway into Q1 2028. The company is also progressing programs such as ALLO-329 in autoimmune diseases.

Allogene Therapeutics, Inc. (NASDAQ:ALLO) is a clinical-stage biotechnology company dedicated to the development of off-the-shelf allogeneic CAR-T cell therapies for cancer and autoimmune diseases. The company’s goal is to provide a scalable, readily available cell therapy derived from healthy donors.

While we acknowledge the risk and potential of ALLO as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ALLO and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.